Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Bristol Myers

Evaluate

Thumbnail
August 03, 2023

Eliquis: the cardio drug that cannot be beat

Thumbnail
July 01, 2019

Big cap stocks grow in first half despite M&A activity, not because of it

Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.

Vantage logo
March 09, 2017

Pfizer and Merck go for an even longer throw of the Javelin

Vantage logo
March 02, 2017

Interview – Grail approaches unicorn status

Vantage logo
February 15, 2017

For Bristol Opdivo gives and it takes away

Vantage logo
January 11, 2017

JP Morgan day two roundup – all talk, very little action

Vantage logo
December 15, 2016

Therapy focus – Immunotherapy closes in on triple-negative tumours

Vantage logo
October 28, 2016

Astra I/O master plan hits a bump in head and neck cancer

Vantage logo
October 19, 2016

Collaborative leukaemia trial orbits moonshot initiative

Vantage logo
October 12, 2016

Esmo event analyser – Tesaro tops the risers while Bristol-Myers is battered

Vantage logo
October 10, 2016

Esmo – Merck carries off first-line NSCLC prize

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up